X4 Pharmaceuticals, Inc. (XFOR)

Nasdaq: XFOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010

Full chart Alerts Compare

Grade4.2

◀ Past 1.8● Present 3.4▶ Future 6.3

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$35.1M+1273.2%

Net income-$79.2M-111.5%

Earnings per share$-1.87+66.5%

Operating cash flow-$85.6M+34.6%

Cash$218M+285.7%

Debt$75.0M0.0%

Shareholders’ equity$186M+741.1%

Shares, diluted42.3M+531.0%

Return on equity-42.5%

The recordfrom its filings

Filings in 202650

Newest filingNov 4 · 10-Q

Annual reportMar 17, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$500,000

Insider buys, 12 months$300,000

Patents granted16

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $17.0MNet income -$80.5MCash from operations -$76.1Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 8, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 7, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 5, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 1, 2026 · SEC EDGAR · Form 144

Notice of intended sale

Open the filing on sec.gov

Sep 21, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 9, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 8, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

X4 Pharmaceuticals, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Boston, MA. License and Other Revenue was 81% of fiscal 2025 revenue.

Newest on the record

Quarterly report on Nov 4. Before it, current report on Oct 29.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About XFOR

X4 Pharmaceuticals, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Boston, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $35 million and a loss of $79 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersBoston, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2010

Fiscal year endsDec 31

SEC number (CIK)1501697

Peers on fileALEC, KYTX, LENZ, LXEO

Who runs it

Financial performance

In fiscal 2025 X4 Pharmaceuticals’s revenue was $35.11 million, up 1273.2% from $2.56 million the year before. It made a net loss of $79.20 million.

Annual report, filed Mar 17, 2026.

Financial statements

The grade

X4 Pharmaceuticals grades 4.2 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past1.8

● Present3.4

▶ Future6.3

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton XFOR · research, not advice